Comparative Pharmacology
Head-to-head clinical analysis: QUINIDEX versus QUINORA.
Peer-Reviewed Evidence
Head-to-head clinical analysis: QUINIDEX versus QUINORA.
QUINIDEX vs QUINORA
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Class Ia antiarrhythmic agent; blocks sodium channels (fast inward sodium current) and prolongs action potential duration; also has anticholinergic and negative inotropic effects.
Quinora (quinidine) is a Class Ia antiarrhythmic agent that blocks sodium channels, prolonging the action potential duration and effective refractory period. It also exhibits anticholinergic and negative inotropic effects.
Quinidine sulfate (QUINIDEX): 200-400 mg orally every 6 hours as arrhythmia suppression; maximum 4 g/day. Route: oral, frequency: every 6 hours.
325 mg orally every 4 to 6 hours as needed, not to exceed 4 g/day.
None Documented
None Documented
Terminal elimination half-life is 6-8 hours in adults with normal renal and hepatic function; may be prolonged to 10-12 hours in congestive heart failure or hepatic impairment.
5-7 hours; prolonged in hepatic impairment (up to 12-15 hours) and in elderly patients.
Renal excretion accounts for approximately 20% unchanged drug; hepatic metabolism (primarily CYP3A4) accounts for 80% with metabolites excreted renally and biliarily; about 5% excreted in feces.
Primarily hepatic (biliary) excretion into feces (~80-90%); renal excretion of unchanged drug accounts for ~10-20%.
Category C
Category C
Antiarrhythmic Agent
Antiarrhythmic Agent